Liquid Biopsy Testing

Expose Cancer with NeoGenomics

Comprehensive tissue testing and liquid biopsy

NeoGenomics offers a broad collection of comprehensive, targeted and single gene liquid biopsy assays for solid tumor cancer and hematologic malignancies. Liquid biopsy testing is a novel approach to genomic profiling and has shown to offer several advantages over tissue biopsy for select clinical scenarios.

 What is liquid biopsy?

Liquid Biopsy refers to the analysis of blood by whole cancer cells (CTCs) or components of cells such as circulating tumor DNA (ctDNA) in order to characterize solid tumors. During the cancer lifecycle, DNA from our cancer cells break down and shed into the bloodstream, called circulating tumor DNA (ctDNA). From a simple blood draw, liquid biopsy testing can be performed to detect specific genetic variations in the ctDNA of a patient’s blood sample that may be causing the cancer to grow.

How does liquid biopsy play a role in cancer testing?

Liquid biopsy testing is a novel approach to genomic profiling and has shown to offer several advantages over tissue biopsy for select clinical scenarios. In the case of limited or insufficient tumor tissue or when a repeat biopsy is required for treatment monitoring, liquid biopsy may be a good option for patients largely because it is a minimally invasive procedure. Additionally, the location of the tumor may be difficult or even dangerous to contact for biopsy and testing of ctDNA by a blood draw might be a suitable alternative to traditional tissue biopsy. Lastly, liquid biopsy testing accounts for potential tumor evolution and heterogeneity since the ctDNA comes from cells anywhere in the body, whereas tissue biopsy is a sample taken from an isolated tumor.

Liquid biopsy supports precision medicine

  • Inform treatment strategies
  • Monitor disease progression
  • Evaluate therapeutic effectiveness


Advantages

Disadvantages

Tissue Biopsy

High diagnostic certainty

Lack of representativeness of tumor heterogeneity

Liquid Biopsy

Can detect tumor heterogeneity

Cannot detect location of tumor mutations


Representative analysis of multiple tumor foci

No diagnostic value if no mutation detected

*InVisionFirst®-Lung is a trademark of Inivata Limited.

Resources

Client Services

For any questions please contact our NeoGenomics’ Client Services at 866.776.5907, option 3 or email Client.Services@neogenomics.com.

Image
InVisionFirst®-Lung icon
InVisionFirst®-Lung
ctDNA liquid biopsy for advanced non-small cell lung cancer (NSCLC)
Image
NeoLAB Solid Tumor icon
NeoLAB® Solid Tumor
Pan-cancer cell-free DNA assay
Image
Liquid Biopsy icon
NeoLAB® Heme
Cell-free DNA/RNA analysis for hematologic diseases